Login
Breaking News
Best Buy   Dick's Sporting Goods   Macy's   Bath & Body Works   Wolfspeed   Arm Holdings   Lyft   Delta Air Lines   Dolby Labs  

Pfizer inc

Major-Pharmaceuticals

PFE


235 East 42nd Street
New York , NY 10017
Website
Investor Relation

News

  • Pfizer Inc. decreased 0.6% to $30.39 after the drugmaker recorded charges related to its COVID vaccine and COVID antiviral treatment Paxlovid.

    The company took a $5.6 billion inventory write-down in the third quarter related to COVID products.

    Revenue in the third quarter plunged 42% to $13.2 billion from $22.6 billion, and the company swung to a net loss of $2.4 billion from a profit of $8.6 billion, and diluted earnings per share declined to ($0.42) from $1.54 a year ago.

    The pharmaceutical company guided full-year 2023 revenue to decline between 39% and More

    Oct 31, 2023

  • Pfizer Inc gained 4.5% to $33.69 after the pharmaceutical company lowered its annual revenue guidance. 

    Pfizer revised lower its 2023 revenue in the range between $58 billion and $61 billion, from the previous estimate between $67 billion and $70 billion on the weakening demand for its Covid products. 

    The company also lowered its full-year adjusted earnings per share outlook to a new range of $1.45 to $1.65 from the previous estimate between $3.25 and $3.45. 

    Oct 16, 2023

Executive/
Director

Executive/Director

Links

10K
10Q
Prospectus

Price

  • Last Close
  • $ 28.72
    $ +0.02 0.07 %
    Aug 29, 2024
  • 52-Week High/Low
  • $35.79 - $25.37
  • YTD
  • -0.2%

  • Trading Volume
  • 638,194
  • Market Cap Full
  • $ 162.2B
  • Shares Outstanding
  • 5646.4M
    Nov 3, 2023

Returns +
Q

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Q1 12.7% -7.2% 6.4% -1.1% -2.7% -5% -1.3% -12.8% -20.5% -3.7%
Q2 -2.8% 19.9% -0.8% 4.5% 1.5% 4% 7.8% 1.3% -10.1% -0.5%
Q3 -5.6% -3% 7.3% 22.3% -17.5% 8% 9.8% -17.3% -9.5% -
Q4 3.6% -3.2% 1.3% -0.6% 7.5% 0.3% 38.1% 18.1% -15.2% -

Returns +
M
J F M A M J J A S O N D
2024 -6% -1.9% 4.5% -0.7% - - - - - - - -
2023 -13.8% -8.1% 0.5% -4.6% -2.2% -3.7% -1.6% -1.9% -6.2% -7.9% -0.4% -5.4%

Returns +
A
    2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
    5%7%4%16%25%-11%-5%61%-14%-44%-0%

Earnings

2015 2016 2017 2018 2019 2020 2021 2022 2023
Q1 0.51 0.67 0.69 0.59 0.68 0.61 0.86 1.37 0.97
Q2 0.56 0.64 0.67 0.65 0.89 0.61 0.98 1.73 0.41
Q3 0.60 0.61 0.67 0.69 1.36 0.39 1.42 1.51 -0.42
Q4 0.53 0.47 0.62 -0.06 -0.06 0.1 0.59 0.86 -
A 2.2 2.4 2.7 1.9 2.8 1.6 3.9 5.5 0.96

Annual Returns

52 Week
High/Low

Annual
Earnings

Chart

Trading Volume

Dividend +

Dividend +

2019 2020 2021 2022 2023 2024
Q1 0.36 0.38 0.39 0.40 0.41 0.42
Q2 0.36 0.38 0.39 0.40 0.41 0.42
Q3 0.36 0.38 0.39 0.40 0.41 0.42
Q4 0.36 0.38 0.39 0.40 0.41 0.42
A 1.44 1.52 1.56 1.6 1.64 1.68

Outstanding Shares
(In Millions) +

Jan 16, 2024
2018 2019 2020 2021 2022 2023
Mar - 5551.8 5547.6 5577.6 5623.3 5619.1
Jun 5849.6 5559.9 5554.8 5597.7 5610.9 5645.3
Sep 5862.1 5531 5556.9 5606.7 5612.4 5646
Dec 5780.5 5534.1 5558.4 5612.9 5613.3 5646.4

Financial Statements
+

Annual
Download

SEC Filings

Date Form Type SEC Filings
Nov 4, 2024 10-Q Financial Statements
Nov 1, 2024 4 Financial Statements
Oct 31, 2024 4 Financial Statements
Oct 16, 2024 4 Financial Statements
Oct 15, 2024 8-K Financial Statements
Oct 15, 2024 4 Financial Statements
Oct 15, 2024 3 Financial Statements
Oct 11, 2024 4 Financial Statements
Oct 3, 2024 SC 13D/A Financial Statements
Oct 2, 2024 4 Financial Statements

Financial Ratios

20222021202020192018
Asset Management
Inventory / Stock Turnover 3.8 3.4 1.1 1.2 1.5
Fixed Asset Turnover 2.3 1.8 1.1 1.3 2.8
Total Asset Turnover 0.5 0.5 0.3 0.3 0.3
Leverage
Debt Ratio 0.6 0.6 1.1 1.1 0.7
Debt – Equity Ratio 0.3 0.5 0.6 0.6 0.5
Interest Coverage 9.8 -7.6 -5.6 -4.3 4.9
Equity multiplier 0.5 0.6 0.6 0.6 0.3
Data Sources Disclaimer